Fei Fei Liu
Overview
Explore the profile of Fei Fei Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
175
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghosh N, Sehgal A, Liu F, Kostic A, Crotta A, De Benedetti M, et al.
Haematologica
. 2024 Oct;
110(3):693-705.
PMID: 39479862
This study assessed the comparative efficacy of lisocabtagene maraleucel (liso-cel) in the open-label, phase II PILOT study (clinicaltrials.gov NCT03483103) versus conventional second-line (2L) chemotherapy regimens in the real world administered...
2.
Liu F, Bartlett M, Craigie S
Pharmacoecon Open
. 2024 Jan;
8(2):171-190.
PMID: 38198111
Background: In this ever-expanding treatment landscape, there is a lack of consolidated health-related quality of life (HRQOL) outcomes and utility reports in relapsed or refractory (R/R) large B cell lymphoma...
3.
Peterse E, Verburg-Baltussen E, Stewart A, Liu F, Parker C, Treur M, et al.
Pharmacoecon Open
. 2023 Aug;
7(6):941-950.
PMID: 37651087
Background: Durable remission has been observed in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) treated with chimeric antigen receptor (CAR) T-cell therapy. Consequently, hazard functions for overall...
4.
Gordon L, Liu F, Braverman J, Hoda D, Ghosh N, Hamadani M, et al.
Haematologica
. 2023 Aug;
109(3):857-866.
PMID: 37646670
In the single-arm, open-label, multicenter, phase II PILOT study, second-line treatment with the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) in patients with relapsed or refractory (R/R) large...
5.
Parker C, Liu F, Deger K, Franco-Villalobos C, Proskorovsky I, Keating S, et al.
Adv Ther
. 2023 Mar;
40(5):2355-2374.
PMID: 36947328
Introduction: The objective of this study was to evaluate the cost-effectiveness of lisocabtagene maraleucel (liso-cel) versus other available chimeric antigen receptor T-cell therapies, including axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel),...
6.
Van Le H, Braun K, Nowakowski G, Sermer D, Radford J, Townsend W, et al.
Leuk Lymphoma
. 2023 Feb;
64(3):573-585.
PMID: 36755418
This study used a real-world population as a synthetic comparator for the single-arm TRANSCEND NHL 001 study (TRANSCEND; NCT02631044) to evaluate the efficacy of lisocabtagene maraleucel (liso-cel) compared with conventional...
7.
Abramson J, Johnston P, Kamdar M, Ibrahimi S, Izutsu K, Arnason J, et al.
Blood Adv
. 2022 Sep;
6(23):5969-5979.
PMID: 36149968
Lisocabtagene maraleucel (liso-cel) has shown promising efficacy in clinical trials for patients with relapsed/refractory large B-cell lymphoma (LBCL). We present health-related quality of life (HRQOL) results from the TRANSFORM study,...
8.
Cartron G, Fox C, Liu F, Kostic A, Hasskarl J, Li D, et al.
Exp Hematol Oncol
. 2022 Mar;
11(1):17.
PMID: 35337365
Background: There are no head-to-head clinical studies comparing chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed or refractory aggressive large B-cell lymphomas. Naive, indirect comparisons may be...
9.
Rahman M, Liu F, Eckel S, Sankaranarayanan I, Shafiei-Jahani P, Howard E, et al.
Environ Health
. 2022 Mar;
21(1):36.
PMID: 35305663
Background: Air pollution has been associated with metabolic disease and obesity. Adipokines are potential mediators of these effects, but studies of air pollution-adipokine relationships are inconclusive. Macrophage and T cells...
10.
Maloney D, Kuruvilla J, Liu F, Kostic A, Kim Y, Bonner A, et al.
J Hematol Oncol
. 2021 Sep;
14(1):140.
PMID: 34493319
Background: In the absence of randomized studies directly comparing chimeric antigen receptor T cell therapies, this study used matching-adjusted indirect comparisons (MAIC) to evaluate the comparative efficacy and safety of...